logo
Plus   Neg
Share
Email

Bombardier Maintains Recently Reduced FY19 Outlook - Quick Facts

While reporting financial results for the first quarter, Bombardier Inc. (BBD_B.TO,BBD_A.TO) on Thursday maintained its outlook that was reduced on April 25, 2019.

For fiscal 2019, the company continues to project revenues in a range of about $17.0 billion, about $1.0 billion lower than originally anticipated and representing about 10 percent organic growth over 2018, excluding currency effects and divestitures.

The Company also maintains its guidance for full year consolidated adjusted EBITDA in a range of $1.50 billion to $1.65 billion, implying growth of almost 20 percent year over year, and consolidated adjusted EBIT in the range of $1.0 billion to $1.15 billion.

Additionally, the company announced that it will consolidate its aerospace assets into a single, streamlined, and fully integrated Bombardier Aviation business unit, which will be led by David Coleal.

As the Company moves to optimize its global manufacturing footprint, Bombardier will pursue the divestiture of the Belfast and Morocco aerostructures businesses.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Just Egg, a plant-based egg alternative, will be available in 2,100 stores owned by grocery chain Kroger Co. later this month. The product launch comes as plant-based meat and egg alternatives gain traction in the country. Just Egg, a product of California-based food technology company Just Inc., will be available at Kroger-owned stores, including Kroger, Fred Meyer and Ralphs. Boeing has delivered the first 787-10 Dreamliner to Vietnam Airlines, the flag carrier of Vietnam, as part of the eight 787-10 Dreamliner airplanes to be delivered on lease through Air Lease. Vietnam Airlines said the 787-10 Dreamliner, claimed by Boeing to be the most fuel-efficient twin-aisle airplane in the industry, will help it raise the customer experience on the Hanoi to Ho Chi Minh route. The U.S. Food and Drug Administration or FDA announced on its website that pharma major Pfizer, Inc. issued recall of two lots of tablets meant to treat acute migraine in adults for concerns over bacteria infection. The pharma company is recalling two lots of Relpax (eletriptan hydrobromide) 40 mg tablets for potential presence of Genus Pseudomonas and Burkholderia bacteria.
Follow RTT